Drug Trial Radar · NCT00389870
Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil
Last checked: Nov 19, 2026Latest source record: Jun 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,198
Actual
Start
Dec 2006
Primary completion
Not stated
Sponsor
- Lead sponsor
- University of LeedsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 19, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cyclosporine may help irinotecan work better by making tumor cells more sensitive to the drug. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Panitumumab may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether irinotecan is more effective when given with or without panitumumab or cyclosporine in treating colorectal cancer. PURPOSE: This randomized phase III trial is studying irinotecan to compare how well it works when given with or without panitumumab or cyclosporine in treating patients with advanced or metastatic colorectal cancer that did not respond to fluorouracil.
Conditions
- Colorectal Cancer
Interventions
panitumumabBiological
cyclosporineDrug
irinotecan hydrochlorideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients treated with irinotecan hydrochloride (Ir) alone vs Ir and cyclosporine (IrC) who are progression-free at 12 weeks
- Overall survival of patients treated with Ir vs Ir and panitumumab (IrP) and no prior cetuximab
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
Royal Bournemouth Hospital
Bournemouth, England, United Kingdom
Sussex Cancer Centre at Royal Sussex County Hospital
Brighton, England, United Kingdom
Bristol Haematology and Oncology Centre
Bristol, England, United Kingdom
Addenbrooke's Hospital
Cambridge, England, United Kingdom
Gloucestershire Oncology Centre at Cheltenham General Hospital
Cheltenham, England, United Kingdom
Eastbourne District General Hospital
Eastbourne, England, United Kingdom
St. Luke's Cancer Centre at Royal Surrey County Hospital
Guildford, England, United Kingdom
Huddersfield Royal Infirmary
Huddersfield, West Yorks, England, United Kingdom
Hinchingbrooke Hospital
Huntingdon, England, United Kingdom
Airedale General Hospital
Keighley, England, United Kingdom
Cookridge Hospital
Leeds, England, United Kingdom
Royal Liverpool University Hospital
Liverpool, England, United Kingdom
UCL Cancer Institute
London, England, United Kingdom
Queen Elizabeth Hospital - Woolwich
London, England, United Kingdom
St. Mary's Hospital
London, England, United Kingdom
Mid Kent Oncology Centre at Maidstone Hospital
Maidstone, England, United Kingdom
Clatterbridge Centre for Oncology
Merseyside, England, United Kingdom
James Cook University Hospital
Middlesbrough, England, United Kingdom
Mount Vernon Cancer Centre at Mount Vernon Hospital
Northwood, England, United Kingdom
Peterborough Hospitals Trust
Peterborough, England, United Kingdom
Dorset Cancer Centre
Poole Dorset, England, United Kingdom
Portsmouth Oncology Centre at Saint Mary's Hospital
Portsmouth Hants, England, United Kingdom
Cancer Research Centre at Weston Park Hospital
Sheffield, England, United Kingdom
South Tyneside District Hospital
South Shields, England, United Kingdom
Royal Marsden - Surrey
Sutton, England, United Kingdom
Great Western Hospital
Swindon, England, United Kingdom
Worthing Hospital
Worthing, England, United Kingdom
Yeovil District Hospital
Yeovil, England, United Kingdom
Edinburgh Cancer Centre at Western General Hospital
Edinburgh, Scotland, United Kingdom
Ysbyty Gwynedd
Bangor, Wales, United Kingdom
Velindre Cancer Center at Velindre Hospital
Cardiff, Wales, United Kingdom
Glan Clwyd Hospital
Rhyl, Denbighshire, Wales, United Kingdom
South West Wales Cancer Institute
Swansea, Wales, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.